Posted by Michael Wonder on 20 Oct 2022
Sinaptica Therapeutics announces FDA breakthrough device designation for its novel non-invasive neurostimulation treatment for Alzheimer’s disease
19 October 2022 - Breakthrough designation is based on positive outcomes from a Phase 2 clinical trial in mild to moderate Alzheimer’s disease patients to be published in a peer reviewed journal imminently.
Sinaptica Therapeutics today announced the US FDA has granted breakthrough device designation to the company’s investigational SinaptiStim – AD System for the treatment of cognitive and functional decline in patients diagnosed with Alzheimer’s disease.
